ATS
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to Personal Folders
Right arrow Download to citation manager
Right arrow Permission Requests
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Levy, J. H.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Levy, J. H.

Ann Thorac Surg 2000;70:S9-S11
© 2000 The Society of Thoracic Surgeons

Platelet inhibitors and bleeding in cardiac surgical patients

Jerrold H. Levy, MDa,b

a Department of Anesthesiology, Emory University School of Medicine, Atlanta, Georgia, USA
b Division of Cardiothoracic Anesthesiology, Emory Healthcare, Atlanta, Georgia, USA

Address reprint requests to Dr Levy, Department of Anesthesiology, Emory University Hospital, 1364 Clifton Rd, NE, Atlanta, GA 30322
e-mail: jerrold_levy{at}emory.org

Presented at the "Managing the Patient Receiving Platelet Inhibitors in Cardiac Surgery" Roundtable Discussion, San Antonio, TX, Jan 22–23, 1999.

A variety of measures may affect bleeding and transfusion requirements in abciximab-treated patients. These measures include recognition of the risk factors for increased bleeding and transfusion requirements, use of proper transfusion practices, conservation or increasing of red cell mass, appropriate heparin dosing and protamine reversal, reversal of anticoagulation, awareness of factors that affect activated clotting time (ACT), and appropriate anticoagulation for cardiopulmonary bypass.




This article has been cited by other articles:


Home page
 J. Thorac. Cardiovasc. Surg.Home page
G. N. Vaccarino, J. Thierer, M. Albertal, M. Vrancic, F. Piccinini, M. Benzadon, H. Raich, and D. O. Navia
Impact of preoperative clopidogrel in off pump coronary artery bypass surgery: a propensity score analysis.
J. Thorac. Cardiovasc. Surg., February 1, 2009; 137(2): 309 - 313.
[Abstract] [Full Text] [PDF]

Home page
 Ann. Thorac. Surg.Home page
C. P. Cannon, S. R. Mehta, and S. F. Aranki
Balancing the Benefit and Risk of Oral Antiplatelet Agents in Coronary Artery Bypass Surgery
Ann. Thorac. Surg., August 1, 2005; 80(2): 768 - 779.
[Abstract] [Full Text] [PDF]

Home page
 Eur. J. Cardiothorac. Surg.Home page
L. Englberger, B. Faeh, P. A. Berdat, F. Eberli, B. Meier, and T. Carrel
Impact of clopidogrel in coronary artery bypass grafting
Eur. J. Cardiothorac. Surg., July 1, 2004; 26(1): 96 - 101.
[Abstract] [Full Text] [PDF]

Home page
 Anesth. Analg.Home page
S. Pothula, V. T. Sanchala, B. Nagappala, and M. A. Inchiosa Jr.
The Effect of Preoperative Antiplatelet/Anticoagulant Prophylaxis on Postoperative Blood Loss in Cardiac Surgery
Anesth. Analg., January 1, 2004; 98(1): 4 - 10.
[Abstract] [Full Text] [PDF]

Home page
 J Am Coll CardiolHome page
R. H. Hongo, J. Ley, S. E. Dick, and R. R. Yee
The effect of clopidogrel incombination with aspirin whengiven before coronary artery bypass grafting
J. Am. Coll. Cardiol., July 17, 2002; 40(2): 231 - 237.
[Abstract] [Full Text] [PDF]

Home page
 PerfusionHome page
L. Y Lee, W. DeBois, K. H Krieger, L. N Girardi, L. Russo, J. McVey, W. Ko, N. K Altorki, R. A Brodman, and O W. Isom
The effects of platelet inhibitors on blood use in cardiac surgery
Perfusion, January 1, 2002; 17(1): 33 - 37.
[Abstract] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
ANN THORAC SURG ASIAN CARDIOVASC THORAC ANN EUR J CARDIOTHORAC SURG
J THORAC CARDIOVASC SURG ICVTS ALL CTSNet JOURNALS
Copyright © 2000 by The Society of Thoracic Surgeons.